TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) S.A.E. Ratings Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
Equities
RMDA
EGS381B1C015
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.3 EGP | -0.43% |
|
-0.86% | +39.39% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +39.39% | 71.8M | C+ | ||
| +61.53% | 856B | C+ | ||
| +38.95% | 631B | B | ||
| -3.66% | 359B | C+ | ||
| +15.06% | 325B | B- | ||
| +9.18% | 297B | C+ | ||
| +5.89% | 234B | A+ | ||
| +16.53% | 226B | B- | ||
| +15.67% | 177B | C+ | ||
| +2.47% | 165B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- RMDA Stock
- Ratings Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
